3LBX

Crystal Structure of the Erythrocyte Spectrin Tetramerization Domain Complex


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.80 Å
  • R-Value Free: 0.299 
  • R-Value Work: 0.268 
  • R-Value Observed: 0.269 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Crystal structure and functional interpretation of the erythrocyte spectrin tetramerization domain complex.

Ipsaro, J.J.Harper, S.L.Messick, T.E.Marmorstein, R.Mondragon, A.Speicher, D.W.

(2010) Blood 115: 4843-4852

  • DOI: 10.1182/blood-2010-01-261396
  • Primary Citation of Related Structures:  
    3LBX

  • PubMed Abstract: 
  • As the principal component of the membrane skeleton, spectrin confers integrity and flexibility to red cell membranes. Although this network involves many interactions, the most common hemolytic anemia mutations that disrupt erythrocyte morphology affect the spectrin tetramerization domains ...

    As the principal component of the membrane skeleton, spectrin confers integrity and flexibility to red cell membranes. Although this network involves many interactions, the most common hemolytic anemia mutations that disrupt erythrocyte morphology affect the spectrin tetramerization domains. Although much is known clinically about the resulting conditions (hereditary elliptocytosis and pyropoikilocytosis), the detailed structural basis for spectrin tetramerization and its disruption by hereditary anemia mutations remains elusive. Thus, to provide further insights into spectrin assembly and tetramer site mutations, a crystal structure of the spectrin tetramerization domain complex has been determined. Architecturally, this complex shows striking resemblance to multirepeat spectrin fragments, with the interacting tetramer site region forming a central, composite repeat. This structure identifies conformational changes in alpha-spectrin that occur upon binding to beta-spectrin, and it reports the first structure of the beta-spectrin tetramerization domain. Analysis of the interaction surfaces indicates an extensive interface dominated by hydrophobic contacts and supplemented by electrostatic complementarity. Analysis of evolutionarily conserved residues suggests additional surfaces that may form important interactions. Finally, mapping of hereditary anemia-related mutations onto the structure demonstrate that most, but not all, local hereditary anemia mutations map to the interacting domains. The potential molecular effects of these mutations are described.


    Organizational Affiliation

    Department of Biochemistry, Molecular Biology, and Cell Biology, Northwestern University, Evanston, IL 60208, USA.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Spectrin alpha chain, erythrocyteA161Homo sapiensMutation(s): 0 
Gene Names: SPTASPTA1
Find proteins for P02549 (Homo sapiens)
Explore P02549 
Go to UniProtKB:  P02549
NIH Common Fund Data Resources
PHAROS:  P02549
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetailsImage
Spectrin beta chain, erythrocyteB185Homo sapiensMutation(s): 0 
Gene Names: SPTBSPTB1
Find proteins for P11277 (Homo sapiens)
Explore P11277 
Go to UniProtKB:  P11277
NIH Common Fund Data Resources
PHAROS:  P11277
Protein Feature View
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.80 Å
  • R-Value Free: 0.299 
  • R-Value Work: 0.268 
  • R-Value Observed: 0.269 
  • Space Group: I 41
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 213.901α = 90
b = 213.901β = 90
c = 31.461γ = 90
Software Package:
Software NamePurpose
MAR345data collection
SHARPphasing
REFMACrefinement
XDSdata reduction
SCALAdata scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2010-03-09
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Advisory, Version format compliance
  • Version 1.2: 2017-11-01
    Changes: Refinement description